These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 19294384)

  • 21. Antibody-targeted chemotherapy of B-cell lymphoma using calicheamicin conjugated to murine or humanized antibody against CD22.
    DiJoseph JF; Popplewell A; Tickle S; Ladyman H; Lawson A; Kunz A; Khandke K; Armellino DC; Boghaert ER; Hamann P; Zinkewich-Peotti K; Stephens S; Weir N; Damle NK
    Cancer Immunol Immunother; 2005 Jan; 54(1):11-24. PubMed ID: 15693135
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CMC-544 (inotuzumab ozogamicin) shows less effect on multidrug resistant cells: analyses in cell lines and cells from patients with B-cell chronic lymphocytic leukaemia and lymphoma.
    Takeshita A; Shinjo K; Yamakage N; Ono T; Hirano I; Matsui H; Shigeno K; Nakamura S; Tobita T; Maekawa M; Ohnishi K; Sugimoto Y; Kiyoi H; Naoe T; Ohno R
    Br J Haematol; 2009 Jun; 146(1):34-43. PubMed ID: 19388933
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Imaging and pharmacokinetics of (64)Cu-DOTA-HB22.7 administered by intravenous, intraperitoneal, or subcutaneous injection to mice bearing non-Hodgkin's lymphoma xenografts.
    Martin SM; O'Donnell RT; Kukis DL; Abbey CK; McKnight H; Sutcliffe JL; Tuscano JM
    Mol Imaging Biol; 2009; 11(2):79-87. PubMed ID: 18949521
    [TBL] [Abstract][Full Text] [Related]  

  • 24. DCDT2980S, an anti-CD22-monomethyl auristatin E antibody-drug conjugate, is a potential treatment for non-Hodgkin lymphoma.
    Li D; Poon KA; Yu SF; Dere R; Go M; Lau J; Zheng B; Elkins K; Danilenko D; Kozak KR; Chan P; Chuh J; Shi X; Nazzal D; Fuh F; McBride J; Ramakrishnan V; de Tute R; Rawstron A; Jack AS; Deng R; Chu YW; Dornan D; Williams M; Ho W; Ebens A; Prabhu S; Polson AG
    Mol Cancer Ther; 2013 Jul; 12(7):1255-65. PubMed ID: 23598530
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CD45 regulates tyrosine phosphorylation of CD22 and its association with the protein tyrosine phosphatase SHP-1.
    Greer SF; Justement LB
    J Immunol; 1999 May; 162(9):5278-86. PubMed ID: 10228003
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Trogocytosis of multiple B-cell surface markers by CD22 targeting with epratuzumab.
    Rossi EA; Goldenberg DM; Michel R; Rossi DL; Wallace DJ; Chang CH
    Blood; 2013 Oct; 122(17):3020-9. PubMed ID: 23821660
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Besides an ITIM/SHP-1-dependent pathway, CD22 collaborates with Grb2 and plasma membrane calcium-ATPase in an ITIM/SHP-1-independent pathway of attenuation of Ca2+i signal in B cells.
    Chen J; Wang H; Xu WP; Wei SS; Li HJ; Mei YQ; Li YG; Wang YP
    Oncotarget; 2016 Aug; 7(35):56129-56146. PubMed ID: 27276708
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Novel synthesizing method of pH-dependent doxorubicin-loaded anti-CD22-labelled drug delivery nanosystem.
    Sun M; Wang J; Lu Q; Xia G; Zhang Y; Song L; Fang Y
    Drug Des Devel Ther; 2015; 9():5123-33. PubMed ID: 26379425
    [TBL] [Abstract][Full Text] [Related]  

  • 29. B cell therapy with the anti-CD22 monoclonal antibody epratuzumab: comment on the editorial by St. Clair and Tedder.
    Goldenberg DM; Stein R; Leonard JP; Steinfeld SD; Dörner T; Burmester GR
    Arthritis Rheum; 2006 Jul; 54(7):2344; author reply 2344-5. PubMed ID: 16802381
    [No Abstract]   [Full Text] [Related]  

  • 30. A Novel Anti-CD22 Anthracycline-Based Antibody-Drug Conjugate (ADC) That Overcomes Resistance to Auristatin-Based ADCs.
    Yu SF; Zheng B; Go M; Lau J; Spencer S; Raab H; Soriano R; Jhunjhunwala S; Cohen R; Caruso M; Polakis P; Flygare J; Polson AG
    Clin Cancer Res; 2015 Jul; 21(14):3298-306. PubMed ID: 25840969
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CD22 is a functional ligand for SH2 domain-containing protein-tyrosine phosphatase-1 in primary T cells.
    Sathish JG; Walters J; Luo JC; Johnson KG; Leroy FG; Brennan P; Kim KP; Gygi SP; Neel BG; Matthews RJ
    J Biol Chem; 2004 Nov; 279(46):47783-91. PubMed ID: 15364920
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Preclinical evaluation of a diabody-based (177)Lu-radioimmunoconjugate for CD22-directed radioimmunotherapy in a non-Hodgkin lymphoma mouse model.
    Weber T; Bötticher B; Arndt MA; Mier W; Sauter M; Exner E; Keller A; Krämer S; Leotta K; Wischnjow A; Grosse-Hovest L; Strumberg D; Jäger D; Gröne HJ; Haberkorn U; Brem G; Krauss J
    Cancer Lett; 2016 Oct; 381(2):296-304. PubMed ID: 27524505
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of a CD22-targeted antibody-saporin conjugate in a xenograft model of precursor-B cell acute lymphoblastic leukemia.
    Kato J; Satake N; O'Donnell RT; Abuhay M; Lewis C; Tuscano JM
    Leuk Res; 2013 Jan; 37(1):83-8. PubMed ID: 23040543
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies.
    DiJoseph JF; Armellino DC; Boghaert ER; Khandke K; Dougher MM; Sridharan L; Kunz A; Hamann PR; Gorovits B; Udata C; Moran JK; Popplewell AG; Stephens S; Frost P; Damle NK
    Blood; 2004 Mar; 103(5):1807-14. PubMed ID: 14615373
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antitumor efficacy of a combination of CMC-544 (inotuzumab ozogamicin), a CD22-targeted cytotoxic immunoconjugate of calicheamicin, and rituximab against non-Hodgkin's B-cell lymphoma.
    DiJoseph JF; Dougher MM; Kalyandrug LB; Armellino DC; Boghaert ER; Hamann PR; Moran JK; Damle NK
    Clin Cancer Res; 2006 Jan; 12(1):242-9. PubMed ID: 16397048
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of CD20, CD22, and HLA-DR targeting for radioimmunotherapy of B-cell lymphomas.
    Pagel JM; Pantelias A; Hedin N; Wilbur S; Saganic L; Lin Y; Axworthy D; Hamlin DK; Wilbur DS; Gopal AK; Press OW
    Cancer Res; 2007 Jun; 67(12):5921-8. PubMed ID: 17575162
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Preclinical and clinical development of inotuzumab-ozogamicin in hematological malignancies.
    Shor B; Gerber HP; Sapra P
    Mol Immunol; 2015 Oct; 67(2 Pt A):107-16. PubMed ID: 25304309
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rituximab-mediated cell signaling and chemo/immuno-sensitization of drug-resistant B-NHL is independent of its Fc functions.
    Vega MI; Huerta-Yepez S; Martinez-Paniagua M; Martinez-Miguel B; Hernandez-Pando R; González-Bonilla CR; Chinn P; Hanna N; Hariharan K; Jazirehi AR; Bonavida B
    Clin Cancer Res; 2009 Nov; 15(21):6582-94. PubMed ID: 19861448
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A comparative analysis of conventional and pretargeted radioimmunotherapy of B-cell lymphomas by targeting CD20, CD22, and HLA-DR singly and in combinations.
    Pagel JM; Orgun N; Hamlin DK; Wilbur DS; Gooley TA; Gopal AK; Park SI; Green DJ; Lin Y; Press OW
    Blood; 2009 May; 113(20):4903-13. PubMed ID: 19124831
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.